ANN E WEBER, PHD

103 Chestnut Street, Apt. 217, Cranford, NJ 07016 | (732) 771-4704 | weberan8@gmail.com

PROFESSIONAL SUMMARY

Accomplished independent consultant and former pharmaceutical executive with a passion for discovering innovative therapeutics to address unmet medical needs. Over 28 years of industrial experience focused on small molecule and peptide drug discovery across therapeutic areas leading to over 40 development candidates, including JANUVIA® (sitagliptin), a treatment for patients with Type 2 diabetes (T2DM), and MARIZEV® (omarigliptin), a once-weekly treatment for T2DM recently approved in Japan; vibegron for the treatment of overactive bladder is in late stage clinical trials. Highly collaborative scientific leader in drug discovery and early development, recognized for building strong teams, setting strategy and managing change. Noted for strong interpersonal skills, talent development, and commitment to advancing women in chemistry.

EXPERIENCE

ANN WEBER PHARMA CONSULTING

December 2015 – present

Independent consultant to biotech and pharma for all aspects of drug discovery including target and lead identification, lead optimization, and development candidate nomination

MERCK & CO

August 1987 – November 2015

Vice President – Lead Optimization Chemistry, Kenilworth, NJ and Boston, MA

November 2013 – November 2015

Responsible for delivering the lead optimization pipeline to the clinic, particularly in the areas of cardiometabolic diseases, infectious diseases, neurological disorders, oncology and asthma; talent recruitment, management and development for department of ~100 lead optimization chemists in Kenilworth and Boston, working in small-molecule and peptide modalities; Cubist integration team co-lead for Discovery Research

Vice President – Kenilworth Discovery Chemistry Site Head, Kenilworth, NJ

September 2011 – October 2013

Discovery of innovative therapeutic agents to treat patients with cardiovascular disease, diabetes, infectious diseases, and neurological disorders; leadership of chemists at Kenilworth site working in Lead Identification, Lead Optimization, and Automated Synthesis & Purification; Joint Steering Committee for Theravance collaboration; leadership and executive sponsorship of strategic initiatives; Six Sigma Executive Black Belt

Vice President – Rahway Discovery Chemistry Site Head, Rahway, NJ

February 2010 – August 2011

Primary focus on the development of new therapies for cardiovascular disease and metabolic disorders; provided leadership for department of ~200 medicinal chemists during re-organization activities following Schering Plough merger; established Rahway Women in Chemistry Lunch, providing networking and leadership opportunities for emerging women leaders across the internal chemistry organization, sponsored the first Merck Women in Chemistry Symposium

Executive Director, Medicinal Chemistry, Rahway, NJ

July 2005 – January 2010

Scientific oversight for teams that identified clinical candidates in the fields of obesity, diabetes, urinary incontinence, and pain; discovery of omarigliptin (approved in Japan Sept 2015), a once weekly agent for diabetes, and vibegron (licensed to Kyorin at Phase III) for urinary incontinence; Diabetes & Obesity Research Licensing Committee; Joint Research Committees for Metabasis and Neuromed collaborations; leadership of Early

Development Teams in diabetes and pain; basic research representative on Urinary Incontinence Product Development Team; chair of the Lead Optimization Work Stream tasked with implementing the new Basic Research Global Operating Strategy in the lead optimization space; Merck Women's Global Constituency Group member

Senior Director, Medicinal Chemistry, Rahway, NJ
March 2002 – June 2005
Leadership of a group of 24 medicinal chemists; identification of clinical candidates in the areas of obesity, diabetes, and pain; co-chair of DPP-4 Back-Up Early Development Team; Diabetes & Obesity Research Licensing Committee

Director, Medicinal Chemistry, Rahway, NJ
November 1997 – February 2002
Leadership for emerging programs in obesity and transplant therapy; initiation of chemistry effort on the DPP-4 inhibitor program for diabetes; co-lead of program core team that identified JANUVIA® (sitagliptin), the first marketed DPP-4 inhibitor for the treatment of patients with type2 diabetes; basic research representative on DPP-4 Early Development Team

Associate Director, Medicinal Chemistry, Rahway, NJ
November 1994 – October 1997
Chemistry group leader of the β3 adrenergic receptor agonist program, leading to the identification of two compounds that entered clinical development; medicinal chemistry representative on the Product Development Team

Research Fellow, Medicinal Chemistry, Rahway, NJ
December 1991 – October 1994
Identification of the first human selective β3 adrenergic receptor agonists for the treatment of obesity

Senior Research Chemist, Medicinal Chemistry, Rahway, NJ
August 1987 – November 1991
Design and synthesis of conformationally-restricted renin inhibitors for hypertension; initiation of the β3 adrenergic receptor agonist program for obesity

Research Assistant, Harvard University, Cambridge, MA
September 1983 – July 1987
Oxazolidinethiones, active ester analogs of oxazolidinone chiral auxiliaries in the asymmetric aldol reaction; asymmetric synthesis of beta-hydroxy amino acids including the total synthesis of Echinocandin D

Research Assistant, California Institute of Technology, Pasadena, CA
September 1982 – August 1987
Initiated graduate work; assisted in laboratory move to Cambridge, MA

Research Assistant / Summer Intern, Monsanto Company, St. Louis, MO
June 1982 – August 1982
Synthesis of novel herbicides for crop protection

EDUCATION

Harvard University
1987 - Ph.D. in Organic Chemistry
Thesis Advisor: David A. Evans

University of Notre Dame
1982 - B.S. in Chemistry, Summa cum Laude
Research Advisor: Conrad J. Kowlaski

AWARDS

1981 Chicago Drug and Chemical Association Undergraduate Scholarship
1981 American Chemical Society Division of Analytical Chemistry Undergraduate Award
1981 National Science Foundation Summer Undergraduate Research Program Participant
1982 Atlantic Richfield Academic Excellence Award
1982 American Institute of Chemists Student Award Certificate
1982 Phi Beta Kappa
1982 Valedictorian, University of Notre Dame
1982 – 1985 National Science Foundation Pre-doctoral Fellowship
2002 American Chemical Society Women Chemists Committee, Women at the Forefront of Chemistry
2007 Merck Directors' Award
2007 Thomas Alva Edison Patent Award (Research & Development Council of New Jersey)
2007 Prix Galien USA for JANUVIA® (team member)
2008 Outstanding Women in Science (New Jersey Association for Biomedical Research)
2009 Award for Drug Discovery (Society for Medicines Research, London) for JANUVIA® (team member)
2010 Robert M. Scarborough Award for Excellence in Medicinal Chemistry (Medicinal Chemistry Division of the American Chemical Society)
2010 Heroes of Chemistry Award for JANUVIA® (American Chemical Society)
2011 Discoverer's Award (Pharmaceutical Research and Manufacturers of America)
2011 Industrial Award (Philadelphia Organic Chemists' Club)
2011 Science and Technology Medal (Research & Development Council of NJ)
2013 Liberty Science Center Women in STEM Honoree (LSC Women's Leadership Council and Board of Trustees)
2015 Gift of Mentoring Award (Metro Women Chemists Committee of the American Chemical Society)

ADVISORY BOARDS

Industrial Advisory Board, Department of Chemistry & Chemical Biology, Rutgers, The State University of NJ
2009 – 2015

Editorial Advisory Board, ACS Medicinal Chemistry Letters
2009 – 2014

PUBLICATIONS

C. J. Kowalski, A. E. Weber, and K. W. Fields; "α-Keto Dianion Precursors *via* Conjugate Additions to Cyclic α-Bromo Enones." *J. Org. Chem.* **1982**, *47*, 5088.

D. A. Evans and A. E. Weber; "Asymmetric Glycine Enolate Aldol Reactions: Synthesis of Cyclosporine's Unusual Amino Acid, MeBmt." *J. Amer. Chem. Soc.* **1986**, *108*, 6757.

D. A. Evans, E. B. Sjogren, A. E. Weber, and R. E Conn; "Asymmetric Synthesis of *Anti*-β-Hydroxy α-Amino Acids." *Tetrahedron Lett.* **1987**, *28*, 39.

D. A. Evans and A. E. Weber; "Synthesis of the Cyclic Hexapeptide Echinocandin D. New Approaches to the Asymmetric Synthesis of β-Hydroxy α-Amino Acids." *J. Amer. Chem. Soc.* **1987**, *109*, 7151.

D. A. Evans, A. E. Weber, T. C. Britton, J. A. Ellman, and E. B. Sjogren; "Asymmetric Synthesis of Amino Acids," in "Peptides: Chemistry and Biology; Proceedings of the Tenth American Peptide Symposium, May 23-28,1987, St. Louis, Missouri", G. R. Marshall, ed., Leiden : ESCOM Science Publishers, 1988, p. 143.

D. H. Rich, C.-Q. Sun, D. Guillaume, B. Dunlap, D. A. Evans, and A. E. Weber; "Synthesis, Biological Activity, and Conformational Analysis of (2*S*,3*R*,4*S*)-MeBmt^1-cyclosporin, a Novel 1-Position Epimer of Cyclosporin A." *J. Med. Chem.* **1989**, *32*, 1982.

W. J. Greenlee and A. E. Weber; "Renin Inhibitors." *Drug News & Perspectives* **1991**, *4*, 332.

A. E. Weber, T. A. Halgren, J. J. Doyle, R. J. Lynch, P. K. S. Siegl, W. H. Parsons, W. J. Greenlee, and A. A. Patchett; "Design and Synthesis of P_2-P_1' Linked Macrocyclic Human Renin Inhibitors." *J. Med. Chem.* **1991**, *34*, 2692.

A. E. Weber, M. G. Steiner, L. Yang, D. S. Dhanoa, J. R. Tata, T. A. Halgren, P. K. S. Siegl, W. H. Parsons, W. J. Greenlee, and A. A. Patchett; "Highly Potent, Orally Active P_2-P_1' Linked Macrocyclic Human Renin Inhibitors," in "Peptides: Chemistry and Biology; Proceedings of the Twelfth American Peptide Symposium, June 16-21, 1991, Cambridge, Massachusetts" J. E. Rivier and J. A. Smith, eds., Leiden: ESCOM Science Publishers, p. 749.

A. E. Weber, M. G. Steiner, P. A. Krieter, A. E. Colletti, J. R. Tata, T. A. Halgren, R. G. Ball, J. J. Doyle, T. W. Schorn, R. A. Stearns, R. R. Miller, P. K. S. Siegl, W. J. Greenlee, and A. A. Patchett; "Highly Potent, Orally Active Diester Macrocyclic Human Renin Inhibitors." *J. Med. Chem.* **1992**, *35*, 3755.

L. Yang, A. E. Weber, W. J. Greenlee, and A. A. Patchett; "Macrocyclic Renin Inhibitors: Synthesis of a Subnanomolar, Orally Active Cysteine Derived Inhibitor." *Tetrahedron Lett.* **1993**, *34*, 7035.

A. E. Weber, R. J. Mathvink, L. Perkins, J. E. Hutchins, M. R. Candelore, L. Tota, C. D. Strader, M. J. Wyvratt, and M. H. Fisher; "Potent, Selective Benzenesulfonamide Agonists of the Human β_3 Adrenergic Receptor." *Bioorg. Med. Chem. Lett.* **1998**, *8*, 1101.

E. R. Parmee, H. O. Ok, M. R. Candelore, L. Tota, L. Deng, C. D. Strader, M. J. Wyvratt, M. H. Fisher, and A. E. Weber; "Discovery of L-755,507: A Subnanomolar Human β_3 Adrenergic Receptor Agonist." *Bioorg. Med. Chem. Lett.* **1998**, *8*, 1107.

M. H. Fisher, A. M. Amend, T. J. Bach, J. M. Barker, E. J. Brady, M. R. Candelore, D. Carroll, M. A. Cascieri, S.-H. L. Chiu, L. Deng, M. J. Forrest, B. Hegarty-Friscino, X. M. Guan, G. J. Hom, J. E. Hutchins, L. J. Kelly, R. J. Mathvink, J. M. Metzger, R. R. Miller, H. O. Ok, E. R. Parmee, R. Saperstein, C. D. Strader, R. A. Stearns, G. M. Thompson, L. Tota, P. P. Vicario, A. E. Weber, J. W. Woods, M. J. Wyvratt, P. T. Zafian, and D. E. MacIntryre; "A Selective Human β_3 Adrenergic Receptor Agonists Increases Metabolica Rate in Rhesus Monkeys." *J. Clin. Invest.* **1998**, 101, 2387.

A. E. Weber; "β_3 Adrenergic Receptor Agonists for the Treatment of Obesity." *Ann. Rep. Med. Chem.* **1998**, *33*, 193.

A. E. Weber, H. O. Ok, R. F. Alvaro, M. R. Candelore, M. A. Cascieri, S.-H. L. Chiu, L. Deng, M. J. Forrest, G. J. Hom, J. E. Hutchins, J. Kao, D. E. MacIntyre, R. J. Mathvink, D. McLoughlin, R. R. Miller, R. C. Newbold, T. V. Olah, E. R. Parmee, L. Perkins, R. A. Stearns, C. D. Strader, J. Szumiloski, Y. S. Tang, L. Tota, P. P. Vicario, M. J. Wyvratt , and M. H. Fisher; "3-Pyridyloxypropanolamine Agonists of the β_3 Adrenergic Receptor with Improved Pharmacokinetic Properties." *Bioorg. Med. Chem. Lett.* **1998**, *8*, 2111-2116.

E. M. Naylor, V. J. Colandrea, M. R. Candelore, M. A. Cascieri, L. F. Colwell, Jr., L. Deng, W. P. Feeney, M. J. Forrest, G. J. Hom, D. E. MacIntyre, C. D. Strader, L. Tota, P.-R. Wang, M. J. Wyvratt, M. H. Fisher, and A. E. Weber; "3-Pyridylethanolamines: Potent and Selective Human β_3 Adrenergic Receptor Agonists." *Bioorg. Med. Chem. Lett.* **1998**, *8*, 3087-3092.

E. R. Parmee, E. M. Naylor, L. Perkins, V. J. Colandrea, H. O. Ok, M. R. Candelore, M. A. Cascieri, L. Deng, W. P. Feeney, M. J. Forrest, G. J. Hom, D. E. MacIntyre, R. R. Miller, R. A. Stearns, C. D. Strader, L. Tota, M. J. Wyvratt, M. H. Fisher, and A. E. Weber; "Human β_3 Adrenergic Receptor Agonists Containing Cyclic Ureido-benzenesulfonamides." *Bioorg. Med. Chem. Lett.* **1999**, *9*, 749.

E. M. Naylor, E. R. Parmee, V. J. Colandrea, L. Perkins, L. Brockunier, M. R. Candelore, M. A. Cascieri, L. F. Colwell, Jr., L. Deng, W. P. Feeney, M. J. Forrest, G. J. Hom, D. E. MacIntyre, C. D. Strader, L. Tota, P.-R. Wang, M. J. Wyvratt, M. H.

Fisher, and A. E. Weber; "Human β3 Adrenergic Receptor Agonists Containing Imidazolidinone and Imidazolone Benzenesulfonamides." *Bioorg. Med. Chem. Lett.* **1999**, *9*, 755.

T. L. Shih, M. R. Candelore, M. A. Cascieri, S.-H. L. Chiu, L. F. Colwell, Jr., L. Deng, W. P. Feeney, M. J. Forrest, G. J. Hom, D. E. MacIntyre, R. R. Miller, R. A. Stearns, C. D. Strader, L. Tota, M. J. Wyvratt, M. H. Fisher, and A. E. Weber; "L-770,644: A Potent and Selective Human β3 Adrenergic Receptor Agonist with Improved Oral Bioavailability." *Bioorg. Med. Chem. Lett.* **1999**, *9*, 1251.

R. J. Mathvink, A. M. Barritta, M. R. Candelore, M. A. Cascieri, L. Deng, L. Tota, C. D. Strader, M. J. Wyvratt, M. H. Fisher, and A. E. Weber; "Potent, Selective Human β3 Adrenergic Receptor Agonists Containing a Substituted Indoline-5-Sulfonamide Pharmacophore." *Bioorg. Med. Chem. Lett.* **1999**, *9*, 1869.

M. R. Candelore, L. Deng, L. Tota, X.-M. Guan, A. Amend, Y. Liu, R. Newbold, M. A. Cascieri, and A. E. Weber; "Potent and Selective Human β3-Adrenergic Receptor Antagonists." *J. Pharmacol. Exper. Ther.* **1999**, *290*, 649.

D. D. Feng, T. Biftu, M. R. Candelore, M. A. Cascieri, L. F. Colwell, Jr., L. Deng, W. P. Feeney, M. J. Forrest, G. J. Hom, D. E. MacIntyre, R. R. Miller, R. A. Stearns, C. D. Strader, L. Tota, M. J. Wyvratt, M. H. Fisher, and A. E. Weber; "Discovery of an Orally Bioavailable Alkyl Oxadiazole β3 Adrenergic Receptor Agonist." *Bioorg. Med. Chem. Lett.* **2000**, *10*, 1427.

T. Biftu, D. Feng, G.-B. Liang, H. Kuo, X. Qian, E. M. Naylor, V. J. Colandrea, M. R. Candelore, M. A. Cascieri, L. F. Colwell, Jr., M. J. Forrest, . J. Hom, D. Euan MacIntyre, R. A. Stearns, C. D. Strader, M. J. Wyvratt, M. H. Fisher, and A. E. Weber; "Synthesis and SAR of Benzyl and phenoxymethylene oxadiazole Benzenesulfonamides as Selective β3 Adrenergic Receptor Agonist Antiobesity Agents." *Bioorg. Med. Chem. Lett.* **2000**, *10*, 1431.

H. O. Ok, L. B. Reigle, M. R. Candelore, M. A. Cascieri, L. F. Colwell, L. Deng, W. P. Feeney, M. J. Forrest, G. J. Hom, D. E. MacIntyre, C. D. Strader, L. Tota, P. Wang, M. J. Wyvratt, M. H. Fisher and A. E. Weber; "Substituted Oxazole Benzenesulfonamides as Potent Human β3 Adrenergic Receptor Agonists." *Bioorg. Med. Chem. Lett.* **2000**, *10*, 1531.

R. J. Mathvink, J. S. Tolman, D. Chitty, M. R. Candelore, M. A. Cascieri, L. F. Colwell, Jr., L. Deng, W. P. Feeney, M. J. Forrest, G. J. Hom, D. E. MacIntyre, L. Tota, M. J. Wyvratt, M. H. Fisher and A. E. Weber; "Potent, Selective 3-Pyridylethanolamine β3 Adrenergic Receptor Agonists Possessing a Thiazole Benzenesulfonamide Pharmacophore." *Bioorg. Med. Chem. Lett.* **2000**, *10*, 1971.

L. L. Brockunier, E. R. Parmee, H. O. Ok, M. R. Candelore, . A. Cascieri, L. F. Colwell, Jr., L. Deng, W. P. Feeney, M. J. Forrest, G. J. Hom, D. E. MacIntyre, L. Tota, M. J. Wyvratt, M. H. Fisher and A. E. Weber; "Human β3 Adrenergic Receptor Agonists Containing 1,2,3-Triazole-Substituted Benzenesulfonamides." *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2111.

E. R. Parmee, L. L. Brockunier, J. He, S. B. Singh, M. R. Candelore, . A. Cascieri, L. Deng, Y. Liu, L. Tota, M. J. Wyvratt, M. H. Fisher and A. E. Weber; "Tetrahydroisoquinoline Derivatives Containing a Benzenesulfonamide Moiety as Potent, Selective Human β3 Adrenergic Receptor Agonists." *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2283.

R. J. Mathvink, J. S. Tolman, D. Chitty, M. R. Candelore, M. A. Cascieri, L. F. Colwell, Jr., L. Deng, W. P. Feeney, M. J. Forrest, G. J. Hom, D. E. MacIntryre, R. R. Miller, R. A.Stearns, L. Tota, M. J. Wyvratt, M. H. Fisher, and A. E. Weber; "Discovery of a Potent, Orally Bioavailable β3 Adrenergic Receptor Agonist, (*R*)-*N*-[4-[2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-[4-[4-(trifluoromethyl)phen-yl]thiazol-2-yl]benzenesulfonamide." *J. Med. Chem.* **2000**, *43*, 3832.

M. J. Forrest, G. Hom, T. Bach, M. R. Candelore, M. A Cascieri, C. Strader, L. Tota, M. H. Fisher, J. Szumiloski, H. O. Ok, A. E. Weber, M. Wyvratt P. Vicario, O. Marko, L. Deng, C. Cioffe, B. Hegarty-Friscino and E. MacIntyre; "L-750355, a human β3 adrenergic receptor agonist; in vitro pharmacology and profile of activity in vivo in the rhesus monkey." *Eur. J. Pharmacol*. **2000**, *407*, 175.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.